title: Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
abstract: BACKGROUND
  Etanercept, a soluble tumour necrosis factor receptor, lessens the severity of psoriasis as measured by physician-reported clinical outcomes. Equally important is the patient perspective on the effect of etanercept therapy on daily life.
  
  
  OBJECTIVE
  To assess patient-reported outcomes (PROs) in patients with psoriasis receiving etanercept therapy.
  
  
  METHODS
  In this multinational, randomized, phase III trial, patients with psoriasis received placebo (n = 193), etanercept 50 mg per week (n = 196) or etanercept 50 mg twice weekly (n = 194) during the initial 12-week, double-blind period. Thereafter, all patients received open-label etanercept (50 mg per week). The following PROs were assessed: Dermatology Life Quality Index (DLQI), Short Form-36 Health Survey (SF-36), patient rating of pruritus, and patient global assessment of psoriasis.
  
  
  RESULTS
  At week 12, DLQI total score improved by 65-70% in patients receiving etanercept compared with 6% in patients receiving placebo (P < 0.0001), and improvement in DLQI was clinically meaningful (> or = 5-point improvement or 0 score) for 72-77% of patients receiving etanercept therapy. All DLQI and SF-36 subscales and the SF-36 physical and mental component summary scores demonstrated significantly greater improvement with etanercept therapy than with placebo, illustrating that etanercept benefits patients with psoriasis across multiple domains that contribute to health-related quality of life. With etanercept therapy, distributions of patient ratings of pruritus and global assessment of disease shifted from moderate to severe (baseline) to minimal to good (week 12). Etanercept-induced benefits of PROs were maintained for patients who reduced their dose after 12 weeks.
  
  
  CONCLUSIONS
  Etanercept therapy improves PROs in patients with psoriasis and makes a meaningful difference to their lives. These results support the efficacy profile of physician-reported clinical measures while providing a more complete understanding of the benefits experienced by patients with psoriasis treated with etanercept.
authors.affiliation: Department of Dermatology, University of Utah Health Sciences Center, 30 N. 1900 E, Salt Lake City, UT 84132-0001, USA. krueger@derm.med.utah.edu
authors.forename: G G
authors.initials: GG
authors.lastname: Krueger
authors.forename: R G
authors.initials: RG
authors.lastname: Langley
authors.forename: A Y
authors.initials: AY
authors.lastname: Finlay
authors.forename: C E M
authors.initials: CE
authors.lastname: Griffiths
authors.forename: J M
authors.initials: JM
authors.lastname: Woolley
authors.forename: D
authors.initials: D
authors.lastname: Lalla
authors.forename: A
authors.initials: A
authors.lastname: Jahreis
mesh_terms: D000328:Adult; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011537:Pruritus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000534:rehabilitation; D011594:Psychometrics; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept